Keynote 177 study showed that anti-PD1 antibody was superior to chemotherapy in terms of response rate and pathology-free survival (PFS) outcomes in first-line treatment of MSI-H CRC. The gene discussed is PDCD1; the disease is colorectal carcinoma.